newsfilter
← Latest News
Business Wire·

Data To Be Presented on Gamida Cell Natural Killer (NK) Cell Therapy Candidate GDA-201 at the International Society for Cell & Gene Therapy 2023 Annual Meeting

New data for batch-to-batch variability and cytotoxicity of GDA-201 show long term stability and unique phenotype of allogeneic NAM-NK cell therapy GDA-201 is in an ongoing Phase 1/2 clinical trial for non-Hodgkin